Job title: VP, Antibody Technologies
Dr. Iffland received her Ph.D. in Molecular and Cell Biology from the Université de Nice Sophia-Antipolis (France) and completed her post-doctoral research training at the Albert Einstein College of Medicine and the Dana-Farber Cancer Institute. She then joined Lexigen, that has later become part of EMD Serono where she worked on antibody characterization, phage display and single B cell cloning. For the last 5 years, her team had adapted those technologies to the OmniAb animals. Dr. Iffland joined Ligand in 2017 to provide scientific guidance and input for the OmniAb franchise and to support current and new partnerships and collaborations.